Peginterferon Beta-1a Shows Antitumor Activity as a Single Agent and Enhances Efficacy of Standard of Care Cancer Therapeutics in Human Melanoma, Breast, Renal, and Colon Xenograft Models.

doi:10.1089/jir.2016.0027

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Peginterferon Beta-1a Shows Antitumor Activity as a Single Agent and Enhances Efficacy of Standard of Care Cancer Therapeutics in Human Melanoma, Breast, Renal, and Colon Xenograft Models.

Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research - 1 Jan 2017

Boccia Antonio, Virata Cyrus, Lindner Daniel, English Nicki, Pathan Nuzhat, Brickelmaier Margot, Hu Xiao, Gardner Jennifer L, Peng Liaomin, Wang Xinzhong, Zhang Xiamei, Yang Lu, Perron Keli, Yco Grace, Kelly Rebecca, Gamez James, Scripps Thomas, Bennett Donald, Joseph Ingrid B, Baker Darren P

Abstract excerpt

Because of its tumor-suppressive effect, interferon-based therapy has been used for the treatment of melanoma. However, limited data are available regarding the antitumor effects of pegylated interferons, either alone or in combination with approved anticancer drugs. We report that treatment of human WM-266-4 melanoma cells with peginterferon beta-1a induced apoptotic markers. Additionally, peginterferon beta-1a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colonic Neoplasms

Share to Drug Therapy, Combination

Share to Interferon-beta

Share to Kidney Neoplasms

Share to Polyethylene Glycols

Share to Tumor Burden

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed

Identifiers

PMID: 27835061
DOI: 10.1089/jir.2016.0027

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Peginterferon Beta-1a Shows Antitumor Activity as a Single Agent and Enhances Efficacy of Standard of Care Cancer Therapeutics in Human Melanoma, Breast, Renal, and Colon Xenograft Models.PMID 27835061Read ↗

Pegylated IFN-α sensitizes melanoma cells to chemotherapy and causes premature senescence in endothelial cells by IRF-1 mediated signaling.Semantic proximity Read ↗

Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasionSemantic proximity Read ↗

Adenovirus-mediated expression of mutated forkhead human transcription like-1 suppresses tumor growth in a mouse melanoma xenograft model.Semantic proximity Read ↗

Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesotheliomaSemantic proximity Read ↗

Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study.Semantic proximity Read ↗

Role of the pro-survival molecule Bfl-1 in melanoma.Semantic proximity Read ↗

PharmGKB summary: peginterferon-α pathway.Semantic proximity Read ↗

Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest.Semantic proximity Read ↗

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignanciesSemantic proximity Read ↗

A novel oncolytic virus engineered with PD-L1 scFv effectively inhibits tumor growth in a mouse modelSemantic proximity Read ↗

In Vitro Effect of Dovitinib (TKI258), a Multi-Target Angiokinase Inhibitor on Aggressive Meningioma Cells.Semantic proximity Read ↗

Antisense targeting of basic fibroblast growth factor and dibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growthSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.